XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
  Cloning
  Genetic Disorders
   Brachydactyly
   Fragile X Syndrome
   Huntington's
   MSUD
   Progeria
  X Chromosome
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

Progeria Channel
subscribe to Progeria newsletter

Latest Research : Genetics : Genetic Disorders : Progeria

   DISCUSS   |   EMAIL   |   PRINT
Drug prevents cell abnormality leading to progeria
Aug 30, 2005 - 7:39:00 PM, Reviewed by: Dr.

The findings offer new clues into how progeria develops and could lead to new drugs to treat the disease and its related disorders, including osteoporosis and hardening of the arteries. UCLA's next step will be to test whether returning the shape of the nuclei to normal stops development of progeria in mice.

 
BACKGROUND: One in 4 million children are born with progeria, a genetic disease marked by accelerated aging and early cardiovascular disease. The children suffer from dwarfism, baldness, wrinkles, hardened arteries and osteoporosis. Most die from heart disease before age 15.

The rare disorder stems from a mutation in a gene that produces an abnormal cellular protein, which attaches itself to structures in the cell's nucleus. The accumulated protein deforms the nucleus, sparking miscommunications with other cells and leading to the genetic disease.

FINDINGS: UCLA scientists studied cells isolated from people with progeria and cultured the cells with a drug that blocked the mutant protein from attaching to the cells' nuclei. The drug significantly reduced the number of human cells with misshapen nuclei. The UCLA team earlier used the same approach to improve the shape of abnormal nuclei from mice genetically engineered to develop progeria.

IMPACT: The findings offer new clues into how progeria develops and could lead to new drugs to treat the disease and its related disorders, including osteoporosis and hardening of the arteries. UCLA's next step will be to test whether returning the shape of the nuclei to normal stops development of progeria in mice.
 

- The Proceedings of the National Academy of Sciences publishes the research online on Aug. 29
 

University of California - Los Angeles

 
Subscribe to Progeria Newsletter
E-mail Address:

 

FUNDING: The National Institute of Aging and the Progeria Research Foundation funded the study.

AUTHORS: Dr. Stephen Young, professor of cardiology; and Loren Fong, Ph.D., assistant professor of cardiology; David Geffen School of Medicine at UCLA

JOURNAL: The Proceedings of the National Academy of Sciences publishes the research online on Aug. 29. A PDF is available upon request. For more information on progeria, see www.progeriaresearch.org.


Related Progeria News
Farnesyl Transferase Inhibitors in Hutchinson-Gilford progeria syndrome
Anti-cancer drugs might work in aging disease
Lamin research project provides clues about premature aging
Drug prevents cell abnormality leading to progeria
Farnesyltransferase inhibitors (FTIs) might be useful in Hutchinson-Gilford Progeria Syndrome


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us